JPH11509848A - N−(4−置換−ベンジル)−2−アミノラクタム誘導体 - Google Patents
N−(4−置換−ベンジル)−2−アミノラクタム誘導体Info
- Publication number
- JPH11509848A JPH11509848A JP9507148A JP50714897A JPH11509848A JP H11509848 A JPH11509848 A JP H11509848A JP 9507148 A JP9507148 A JP 9507148A JP 50714897 A JP50714897 A JP 50714897A JP H11509848 A JPH11509848 A JP H11509848A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- benzylamino
- formula
- hydrogen
- fluorobenzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式(I) [式中、 mは、0、1、2、又は3であり; nは、0、1、2、又は3であり; Xは、−O−、−S−、−CH2−、又は−NH−であり; R及びR1の各々は独立に、水素、C1−C6アルキル、ハロゲン、ヒドロキシ、 C1−C4アルコキシ、又はトリフルオロメチルであり; R2、R3及びR4の各々は独立に、水素、ヒドロキシ基によって場合により置換 されたC1−C6アルキル、又はC3−C7シクロアルキルである] を有する化合物、又は医薬として許容できるその塩。 2. 式中、mは、1又は2であり; nは、1又は2であり; Xは、−O−、−S−、又は−NH−であり; Rは、水素であり; R1は、水素又はハロゲンであり; R2及びR4の各々は独立に、水素又はC1−C4アルキルであり; R3は、水素、又はヒドロキシ基で場合により置換されたC1−C4アルキルであ る; ことを特徴とする請求項1に記載の式(T)を有する化合物、又は医薬として許 容できるその塩。 3. 式中、mは、1であり; nは、1であり; Xは、−O−又は−NH−であり; R1は、水素又はハロゲンであり; R2は、水素又はC1−C4アルキルであり; R3は、水素、又はヒドロキシで場合により置換されたC1−C4アルキルであり ; R及びR4は、水素である; ことを特徴とする請求項1に記載の式(I)を有する化合物、又は医薬として許 容できるその塩。 4. 3−[4−(3−フルオロベンジルオキシ)ベンジルアミノ]−ピロリジ ン−2−オン; 3−[4−(3−クロロベンジルオキシ)ベンジルアミノ]−ピロリジン−2 −オン; 3−[4−(4−クロロベンジルオキシ)ベンジルアミノ]−ピロリジン−2 −オン; 3−[4−(3−ブロモベンジルオキシ)ベンジルアミノ]−ピロリジン−2 −オン; 3−[4−(4−フルオロベンジルオキシ)ベンジルアミノ]−ピロリジン− 2−オン; 3−[4−(2−フルオロベンジルオキシ)ベンジルアミノ]−ピロリジン− 2−オン; 3−[4−(3−フルオロベンジルオキシ)ベンジルアミノ]−アゼチジン− 2−オン; 3−[4−(3−フルオロベンジルオキシ)ベンジルアミノ]−ピペリジン− 2−オン; 3−[4−(3−フルオロベンジルオキシ)ベンジルアミノ] −アゼパン−2−オン; 3−[4−(3−フルオロベンジルアミノ)ベンジルアミノ]−ピロリジン− 2−オン; 3−[4−(ベンジルスルファニル)ベンジルアミノ]−ピロリジン−2−オ ン; 3−{[4−(3−フルオロベンジルオキシ)ベンジル]メチルアミノ}−ピ ロリジン−2−オン; 3−{[4−(3−フルオロベンジルオキシ)ベンジル]メチルアミノ}−1 −ヒドロキシメチル−ピロリジン−2−オン; 3−[4−(3−フルオロベンジルオキシ)ベンジルアミノ]−1−メチル− ピロリジン−2−オン; 3−{[4−(3−クロロベンジルオキシ)ベンジル]メチルアミノ}−ピロ リジン−2−オン; 3−{[4−(3−ブロモベンジルオキシ)ベンジル]メチルアミノ}−ピロ リジン−2−オン; からなる群から選択される(存在する場合は、単一異性体、又はそれらの異性体 の混合物である)化合物、あるいは医薬として許容できるその塩。 5. 請求項1に記載の式(I)を有する化合物、又は医薬として許容できるそ の塩の製造方法であって、 a)式(II) [式中、n、R、R1、及びXは、請求項1に定義の通りである]を有する化合 物を、式(III) [式中、m、R3及びR4は、請求項1に記載の通りである]を有する化合物と反 応させて、式(I)[式中、R2は水素である]を有する化合物を得ること;あ るいは b)式(IV) [式中、R、R1、R3、R4、m、n、及びXは、請求項1に記載の通りである ]を有する化合物を、式(V)又は(VI) R′2W (V) R″2CHO (VI) [式中、Wはハロゲン原子であり;R′2はC1−C4アルキルであり、及びR″2 は水素又はC1−C3アルキルである]を有する化合物と反応させて、本発明の化 合物[式中、R2はC1−C4アルキルである]を得ること;及び、所望ならば、 本発明の化合物を本発明の別の化合物に変換すること、及び/又は、所望ならば 、本発明の化合物を医薬として許容できる塩に変換すること、及び/又は、所望 ならば、塩を遊離化合物に変換すること、及び/又は、所望ならば、本発明の化 合物の異性体の混合物を単一異性体に分離すること; を含むことを特徴とする上記方法。 6. 適切な担体及び/又は希釈剤、及び活性剤として請求項1に記載の式(I )を有する化合物又は医薬として許容できるその塩を含む医薬組成物。 7. 治療用活性物質として使用するための請求項1に記載の式(I)を有する 化合物又は医薬として許容できるその塩。 8. 抗癲癇剤、抗パーキンソン病剤、神経保護剤、抗鬱剤、鎮痙剤、及び睡眠 剤として、並びに神経変性疾患の治療と予防のために使用するための請求項1に 記載の式(I)を有する化合物又は医薬として許容できるその塩。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9515411.8A GB9515411D0 (en) | 1995-07-27 | 1995-07-27 | N-(4-substituted-benzyl)-2-aminolactam derivatives |
GB9515411.8 | 1995-07-27 | ||
PCT/EP1996/002962 WO1997005111A1 (en) | 1995-07-27 | 1996-07-05 | N-(4-substituted-benzyl)-2-aminolactam derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11509848A true JPH11509848A (ja) | 1999-08-31 |
JP3939755B2 JP3939755B2 (ja) | 2007-07-04 |
Family
ID=10778351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50714897A Expired - Lifetime JP3939755B2 (ja) | 1995-07-27 | 1996-07-05 | N−(4−置換−ベンジル)−2−アミノラクタム誘導体 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5912242A (ja) |
EP (1) | EP0842152B1 (ja) |
JP (1) | JP3939755B2 (ja) |
AT (1) | ATE199013T1 (ja) |
AU (1) | AU6611696A (ja) |
BR (1) | BR9609847A (ja) |
CA (1) | CA2226886C (ja) |
DE (1) | DE69611728T2 (ja) |
ES (1) | ES2154830T3 (ja) |
GB (1) | GB9515411D0 (ja) |
IL (1) | IL122706A0 (ja) |
WO (1) | WO1997005111A1 (ja) |
ZA (1) | ZA965997B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007511564A (ja) * | 2003-11-21 | 2007-05-10 | ニューロン・ファーマシューティカルズ・ソチエタ・ペル・アチオニ | 3−アミノピロリドン誘導体 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
ATE319447T1 (de) * | 1999-08-16 | 2006-03-15 | Revaax Pharmaceuticals Llc | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen |
US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
JP4350508B2 (ja) | 2001-09-03 | 2009-10-21 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途 |
EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
EP1524267A1 (en) | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Substituted benzylaminoalkylene heterocycles |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
CA2758029A1 (en) * | 2009-04-29 | 2011-11-04 | Rexahn Pharmaceuticals, Inc. | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders |
US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU518986B2 (en) * | 1977-10-11 | 1981-10-29 | Takeda Chemical Industries Ltd. | Lactams |
US4719207A (en) * | 1984-06-25 | 1988-01-12 | Yamanouchi Pharmaceutical Co., Ltd. | CNS active substituted azetidinone compounds |
GB8823605D0 (en) * | 1988-10-07 | 1988-11-16 | Merck Sharp & Dohme | Therapeutic agents |
-
1995
- 1995-07-27 GB GBGB9515411.8A patent/GB9515411D0/en active Pending
-
1996
- 1996-07-05 US US08/981,493 patent/US5912242A/en not_active Expired - Lifetime
- 1996-07-05 DE DE69611728T patent/DE69611728T2/de not_active Expired - Lifetime
- 1996-07-05 IL IL12270696A patent/IL122706A0/xx unknown
- 1996-07-05 ES ES96925667T patent/ES2154830T3/es not_active Expired - Lifetime
- 1996-07-05 AU AU66116/96A patent/AU6611696A/en not_active Abandoned
- 1996-07-05 CA CA002226886A patent/CA2226886C/en not_active Expired - Lifetime
- 1996-07-05 BR BR9609847A patent/BR9609847A/pt not_active Application Discontinuation
- 1996-07-05 WO PCT/EP1996/002962 patent/WO1997005111A1/en active IP Right Grant
- 1996-07-05 AT AT96925667T patent/ATE199013T1/de not_active IP Right Cessation
- 1996-07-05 EP EP96925667A patent/EP0842152B1/en not_active Expired - Lifetime
- 1996-07-05 JP JP50714897A patent/JP3939755B2/ja not_active Expired - Lifetime
- 1996-07-15 ZA ZA965997A patent/ZA965997B/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007511564A (ja) * | 2003-11-21 | 2007-05-10 | ニューロン・ファーマシューティカルズ・ソチエタ・ペル・アチオニ | 3−アミノピロリドン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
DE69611728T2 (de) | 2001-05-10 |
ES2154830T3 (es) | 2001-04-16 |
CA2226886A1 (en) | 1997-02-13 |
WO1997005111A1 (en) | 1997-02-13 |
GB9515411D0 (en) | 1995-09-27 |
ZA965997B (en) | 1997-01-31 |
ATE199013T1 (de) | 2001-02-15 |
IL122706A0 (en) | 1998-08-16 |
CA2226886C (en) | 2007-01-30 |
JP3939755B2 (ja) | 2007-07-04 |
BR9609847A (pt) | 1999-03-09 |
DE69611728D1 (de) | 2001-03-08 |
AU6611696A (en) | 1997-02-26 |
EP0842152A1 (en) | 1998-05-20 |
US5912242A (en) | 1999-06-15 |
EP0842152B1 (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI114792B (fi) | Menetelmä terapeuttisesti aktiivisten N-fenyylialkyyli-substituoitujen alfa-aminokarboksamidi-johdannaisten valmistamiseksi | |
EP1680400B1 (fr) | Derives de n-[ phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[(azepan-2-yl) phenylmethyl]benzamide, leur preparation et leur application en therapeutique | |
EP0673928B1 (fr) | Nouveaux dérivés de la N-(3,4-dichlorophényl-propyl)-pipéridine comme antagonistes sélectifs du récepteur NK3 humain | |
EP0559538B1 (fr) | Sels quaternaires de pipéridines 4-substitués, leur préparation et compositions pharmaceutiques les contenant | |
KR890001550B1 (ko) | 벤자제핀 유도체의 제조방법 | |
EP1682503B1 (fr) | Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
JPH11509848A (ja) | N−(4−置換−ベンジル)−2−アミノラクタム誘導体 | |
US5945454A (en) | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | |
WO2004013101A2 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
WO2004013100A2 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
JP3542599B2 (ja) | 置換(アリールアルコキシベンジル)アミノプロパンアミド誘導体及びその製造方法 | |
FR2740134A1 (fr) | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant | |
EP0734379A1 (fr) | Nouveaux derives de 2-arylalkenyl-azacycloalkanes ligands aux recepteurs sigma, leur procede de preparation et leur application en therapeutique | |
US5449692A (en) | Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation | |
JP2000516634A (ja) | カッパアゴニストとしてのピロリジニルおよびピロリニルエチルアミン化合物 | |
EP0929550A1 (fr) | DERIVES DE $i(N)-(BENZOTHIAZOL-2-YL)PIPERIDINE-1-ETHANAMINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
LU87129A1 (fr) | Nouvel acide piperazinecarboxylique,sa preparation et son utilisation comme medicament | |
WO1998043964A1 (en) | 2-[(3-substituted)-5-isoxazolylmethylamino]alkanamide derivatives | |
JPH02138252A (ja) | 5‐置換1‐〔4‐(1‐ピロリジニル)‐2‐ブチニル〕‐2‐ピロリドン類および類似化合物 | |
JPH0441144B2 (ja) | ||
US5716936A (en) | Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders | |
FR2775687A1 (fr) | Nouveaux composes du benzocyclobutane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
KR20010033998A (ko) | 신경학적 질병 치료용 1,4-디아자시클로헵탄 유도체 | |
US5093355A (en) | Benzylpyrrolidine derivatives as dopamine agonists | |
FR2688218A1 (fr) | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061017 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20061004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070313 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070329 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110406 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120406 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120406 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130406 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130406 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140406 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |